P47.11 COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib
Explore this paper's citation graph
- Type
- article
- Published
- 2021-10-01
- Cited by
- 17
- References
- 0
- Access
- Open access
- OpenAlex
- https://openalex.org/W3205941621
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:239189518
Keywords
Osimertinib, Medicine, T790M, Lung cancer, Chemotherapy
References
No references recorded for this paper.
Cited by
- Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis
- Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
- Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance
- New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
- A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms
- Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.
- Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings
- A Nomogram for Predicting Survival for Patients with Brain Metastatic and EGFR Mutation Advanced Non-Small Cell Lung Cancer
- CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression.
- Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics
- A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.
- A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
- Updates on the treatment of epidermal growth factor receptor‐mutant non–small cell lung cancer
- Evolving treatment for advanced Non-small cell lung cancer harbouring common EGFR activating mutations.
- Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
- Current and Emerging Treatment Landscape of Common EGFR-Mutated Advanced Non-small Cell Lung Cancer
Related papers
- Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
- EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
- Impact of next-generation sequencing on clinical outcomes in advanced EGFR-mutant lung cancer patients after resistance to osimertinib.
- P3.01-037 Understanding Mechanisms of Resistance to Osimertinib by Circulating Tumor DNA Genotyping in Advanced Non-Small-Cell Lung Cancer
- P3.02b-032 Association between EGFR T790M Mutation Copy Numbers in Cell-Free Plasma DNA and Response to Osimertinib in Advanced NSCLC: Topic: EGFR Biomarkers
- EP12.01-23 Combination of Osimertinib plus Capmatinib in a Patient with EGFR-mutant, T790M positive and MET amplification: A Case Report
- MA15.07 Different Responses to Osimertinib in Primary and Acquired EGFR T790M-Mutant NSCLC Patients
- Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
- JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790M-Mutant NSCLC Patients
- Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations